SOUTH SAN FRANCISCO, CA--(Marketwired - Aug 11, 2015) - Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at an initial public offering price of $20.00 per share. All shares of common stock are being offered by GBT. In addition, the underwriters have a 30-day option to purchase up to an additional 900,000 shares of common stock from GBT. The shares are expected to begin trading on the NASDAQ Global Select Market on August 12, 2015 under the ticker symbol "GBT."
Morgan Stanley and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company and Wedbush PacGrow are acting as co-managers. The offering is expected to close on August 17, 2015, subject to the satisfaction of customary closing conditions.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on August 11, 2015. The offering is being made solely by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 803-9204 or by email at [email protected] or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, Facsimile (212) 902-9316 or emailing [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a clinical stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its initial product candidate, GBT440, as an oral, once-daily prophylactic therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in both healthy subjects and SCD patients in a randomized, placebo-controlled, double-blind Phase 1/2 clinical trial. In addition to GBT440 for the treatment of SCD, GBT is engaged in research and development activities targeted toward hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF), and hereditary angioedema (HAE).